In a recent study examining the relationship between AD and IGFBP2 levels across a spectrum of 300 human AD patients and two transgenic mouse models of AD, investigators found cerebrospinal fluid (CSF) IGFBP2 levels correlated with CSF tau levels and brain atrophy in non-hippocampal regions71. This evidence concerns the gene MAPT and Alzheimer disease.